RA Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

RA Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-80,515	Closed	-$33.8M	–	32
2019 Q1	$33.8M	Hold	80,515	–	–	1.46%	20
2018 Q4	$24.5M	Buy	+80,515	New	+$26M	1.43%	20
2017 Q2	–	Sell	-11,807	Closed	-$4.06M	–	26
2017 Q1	$4.06M	Hold	11,807	–	–	0.5%	23
2016 Q4	$4.13M	Hold	11,807	–	–	0.58%	22
2016 Q3	$4.74M	Buy	11,807 +2,084	+21%	+$1.06M	0.49%	26
2016 Q2	$5.78M	Hold	9,723	–	–	0.8%	24
2016 Q1	$4.89M	Buy	+9,723	New	+$4.84M	0.63%	32
2015 Q2	–	Sell	-91	Closed	-$775K	–	67
2015 Q1	$775K	Hold	91	–	–	0.08%	55
2014 Q4	$799K	Buy	+91	New	+$528K	0.09%	49

Other funds holding EIGR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

RA Capital Management's EIGR Position: Q2 2019 in Review

RA Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2019, closing a stake of 80,515 shares — an estimated $33.8M sold.

RA Capital Management first reported a position in EIGR in Q4 2014 and held it in 9 quarters. The position peaked at $33.8M in Q1 2019. 78 funds tracked by Wall St. Rank hold EIGR as of Q2 2019.

RA Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
RA Capital Management sold 80,515 Eiger BioPharmaceuticals, Inc. shares in Q2 2019, an estimated $33.8M.
RA Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
RA Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $33.8M in Q1 2019.
78 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2019.

Based on RA Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.